Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Head and Neck Cancer
Interventions: Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab, LymphDetect assay, Surgery +/- neoadjuvant pembrolizumab; Drug · Radiation · Diagnostic Test + 1 more
Lead sponsor: Kevin Contrera; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Treatment Resistant Depression
Interventions: Lithium, Placebo, Ketamine; Drug
Lead sponsor: William V. Bobo, M.D.; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers
Interventions: MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD; Drug
Lead sponsor: Epirium Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Marlton, New Jersey • Austin, Texas

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Rapid-Acting Insulin, Long acting insulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 15 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Prevention, Pre-Exposure Prophylaxis (PrEP)
Interventions: RAPID Response peer navigation, Emtricitabine/tenofovir disoproxil fumarate (F/TDF); Behavioral · Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Rapidly Escalating Migraine
Interventions: DFN-11; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: ACL, Opioid Use, Cryotherapy Effect, Vibration; Exposure, Pain, Postoperative
Interventions: VibraCool mechanical stimulation and neuromodulatory therapeutic device, Cryocompression (Game Ready, Bregs) device, Standard ice packs; Device
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: TAK-329, Insulin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Respiratory Rate Monitoring
Interventions: Physiological Monitoring with SpO₂ Sensors and Capnography; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 4 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: Lifestyle Factors, Customized use of Dietary Supplements, Currently Accepted Asthma Care Guidelines; Behavioral · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 19 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colitis, Ulcerative
Interventions: SRT2104; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Alcohol Consumption, Alcohol, Hangover Symptoms, NAC, Veisalgia
Interventions: Supplement, Placebo; Dietary Supplement
Lead sponsor: Medical Life Care Planners, LLC; Other
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Physical Deconditioning, Mobility Decline
Interventions: Gerofit Power Training, Gerofit Standard of Care; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cerebral Palsy
Interventions: Short Burst Interval Treadmill Training (SBLTT), Traditional Locomotor Treadmill Training (TLTT); Behavioral
Lead sponsor: Kristie Bjornson; Other
Eligibility: 6 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana • Seattle, Washington

Conditions: Prophylaxis of Organ Rejection
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Interventions: ASTX727; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more

Conditions: Prostate Cancer
Interventions: GnRh (Leuprolide), Testosterone Gel, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Natriuretic Peptides, Metabolic Syndrome
Interventions: Study diet, Glucose Challenge; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Lymphocytic Leukemia, CML (Chronic Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), Acute Lymphoblastic Leukemia, AML (Acute Myelogenous Leukemia)
Interventions: MVST, MVSTr; Biological
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions: Point-of-care STI tests, Standard of care STI testing; Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: Female only
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: Questionnaire, Stool sample, Skin swab, Oral rinse; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Substance Use Disorder (SUD), HIV (Human Immunodeficiency Virus), Viral Suppression of HIV Infection
Interventions: DEST2nation model, Standard of care referral; Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Long Island City, New York • Philadelphia, Pennsylvania

Conditions: Stress Reduction, Healthy Relationships, Emotional Wellbeing
Interventions: AER for Stronger Communities, Placebo Comparator; Behavioral · Other
Lead sponsor: Loyola University Chicago; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

VibraCool Device to Reduce Pain and Opioid Use After Anterior Cruciate Ligament Reconstruction (ACLR)

TAK-329 Glucose Clamp Study

Respiration From Pleth Validation

Functional Medicine in Asthma (FAst) Study

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

Rapid BAC Reduction with Nutraceutical Blend Study

Development of a Power Training Program to Improve Mobility in Older Veterans

Short-Burst Interval Treadmill Training Cerebral Palsy

Bioequivalency Study of Mycophenolate Mofetil 250 mg Capsules Under Fasted Conditions

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Racial Differences in the Natriuretic Peptide Response to Glucose Challenge

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Improving Maternal and Child Health Through Point-of-care STI Testing

Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry

Decentralized, Status Neutral, Stakeholder-engaged, Post-incarceration Intervention for People Living With and at Risk for HIV

Afghan Evacuee Resettlement for Stronger Communities (AER)